| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -179,540 | -114,004 | -149,770 | -133,213 |
| Provision for income taxes | 873 | 947 | 1,310 | 303 |
| Net loss | -180,413 | -114,951 | -151,080 | -133,516 |
| Earnings per share, basic, total | -1.81 | -1.17 | -1.57 | -1.4 |
| Earnings per share, diluted, total | -1.81 | -1.17 | -1.57 | -1.4 |
| Weighted average number of shares outstanding, basic, total | 99,771,297 | 98,460,445 | 96,288,650 | 95,493,996 |
| Weighted average number of shares outstanding, diluted, total | 99,771,297 | 98,460,445 | 96,288,650 | 95,493,996 |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)